ERBB2 and breast cancer: Two clinical trials are recruiting patients to test its administration in combination with either trastuzumab and pertuzumab in metastatic HER2+ BC or with atezolizumab and nab-paclitaxel in advanced TNBC patients (NCT03135171 and NCT03424005).